TGAACGTGTC GGTGGTGTCT GAGGAGGTCT GCAGTAAGCT CTATGACCCG CTGT

234

- (2) INFORMATION FOR SEQ ID NO:46:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 590 base pairs(B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: cDNA
 - (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46:

ACTTTTTATT	TAAATGTTTA	TAAGGCAGAT	CTATGAGAAT	GATAGAAAAC	ATGGTGTGTA	60
ATTTGATAGC	AATATTTTGG	AGATTACAGA	GTTTTAGTAA	TTACCAATTA	CACAGTTAAA	120
AAGAAGATAA	TATATTCCAA	GCANATACAA	AATATCTAAT	GAAAGATCAA	GGCAGGAAAA	180
TGANTATAAC	TAATTGACAA	TGGAAAATCA	ATTITAATGT	GAATTGCACA	TTATCCTTTA	240
AAAGCTTTCA	AAANAAANAA	TTATTGCAGT	CTANTTAATT	CAAACAGTGT	TAAATGGTAT	300
CAGGATAAAN	AACTGAAGGG	CANAAAGAAT	TAATTTTCAC	TTCATGTAAC	NCACCCANAT	360
TTACAATGGC	TTAAATGCAN	GGAAAAAGCA	GTGGAAGTAG	GGAAGTANTC	AAGGTCTTTC	420
TGGTCTCTAA	TCTGCCTTAC	TCTTTGGGTG	TGGCTTTGAT	CCTCTGGAGA	CAGCTGCCAG	480
GGCTCCTGTT	ATATCCACAA	TCCCAGCAGC	AAGATGAAGG	GATGAAAAAG	GACACATGCT	540
GCCTTCCTTT	GAGGAGACTT	CATCTCACTG	GCCAACACTC	AGTCACATGT		590

- (2) INFORMATION FOR SEQ ID NO:47:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 774 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: cDNA
 - (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

ACAAGGGGGC	ATAATGAAGG	AGTGGGGANA	GATTTTAAAG	AAGGAAAAA	AACGAGGCCC	60
TGAACAGAAT	TTTCCTGNAC	AACGGGGCTT	CAAAATAATT	TTCTTGGGGA	GGTTCAAGAC	120
GCTTCACTGC	TTGAAACTTA	AATGGATGTG	GGACANAATT	TTCTGTAATG	ACCCTGAGGG	180
CATTACAGAC	GGGACTCTGG	GAGGAAGGAT	AAACAGAAAG	GGGACAAAGG	CTAATCCCAA	240
AACATCAAAG	AAAGGAAGGT	GGCGTCATAC	CTCCCAGCCT	ACACAGTTCT	CCAGGGCTCT	300
CCTCATCCCT	GGAGGACGAC	AGTGGAGGAA	CAACTGACCA	TGTCCCCAGG	CTCCTGTGTG	360
CTGGCTCCTG	GTCTTCAGCC	CCCAGCTCTG	GAAGCCCACC	CTCTGCTGAT	CCTGCGTGGC	420
CCACACTCCT	TGAACACACA	TCCCCAGGTT	ATATTCCTGG	ACATGGCTGA	ACCTCCTATT	480
CCTACTTCCG	AGATGCCTTG	CTCCCTGCAG	CCTGTCAAAA	TCCCACTCAC	CCTCCAAACC	540
ACGGCATGGG	AAGCCTTTCT	GACTTGCCTG	ATTACTCCAG	CATCTTGGAA	CAATCCCTGA	600
TTCCCCACTC	CTTAGAGGCA	AGATAGGGTG	GTTAAGAGTA	GGGCTGGACC	ACTTGGAGCC	660
AGGCTGCTGG	CTTCAAATTN	TGGCTCATTT	ACGAGCTATG	GGACCTTGGG	CAAGTNATCT	720
TCACTTCTAT	GGGCNTCATT	TTGTTCTACC	TGCAAAATGG	GGGATAATAA	TAGT	774

- (2) INFORMATION FOR SEQ ID NO:48:
 - (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 124 base pairs

BNS page 56

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(21) International Publication Number: WO 98/37093 (22) International Application Number: PCT/US98/03492 (23) International Application Number: PCT/US98/03492 (24) International Filing Date: 25 February 1998 (25.02.98) (25) International Filing Date: 25 February 1998 (25.02.98) (26) Priority Data: 08/906.099 25 February 1997 (25.02.97) US 08/904.804 1 August 1997 (01.08.97) US 08/902.986 1 August 1997 (01.08.97) US 08/902.996 9 February 1998 (09.02.98) (27) Inventors: XU, Jiangchun; 15805 Southeast 43rd Place, Bellevue, WA 98006 (US), DILLON, Davin, C.; 21607 N.E. 24th Street, Redmond, WA 98033 (US). (28) International Publication Date: 27 August 1998 (27.08.98) (81) Designated States: AL, AM, AT, AU, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, IP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, VM, DM, GM, KM, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TI, TM, TT, UA, UZ, VM, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM, European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM, European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM, European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM, European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM, European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM, European patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM, European
(21) International Application Number: PCT/US98/03492 (22) International Filing Date: 25 February 1998 (25.02.98) (23) International Filing Date: 25 February 1998 (25.02.98) (24) International Filing Date: 25 February 1998 (25.02.98) (25) Priority Data: 08/904.804 August 1997 (10.08.97) US 08/904.804 August 1997 (10.
(22) International Filing Date: 25 February 1998 (25.02.98) (23) International Filing Date: 25 February 1998 (25.02.98) (24) Priority Data: (25) O8/806,099 (26) Pebruary 1997 (25.02.97) (27) O8/904,804 (28) Pebruary 1998 (09.02.98) (28) O9/020,956 (29) February 1998 (09.02.98) (29) O9/020,956 (20) Pebruary 1998 (09.02.98) (20) O9/020,956 (21) O8/904,804 (22) Inventors: CORIXA CORPORATION (US/US): Suite 200. 1124 Columbia Street, Seattle, WA 98104 (US). (27) Inventors: XU, Jiangchun: 15805 Southeast 43rd Place, Bellevue, WA 98006 (US). DILLON, Davin, C.; 21607 N.E. 24th Street, Redmond, WA 98053 (US). (24) Agents: MAKI, David, J. et al.; Seed and Berry LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104–7092 (US). (25) Tittle: COMPOUNDS FOR IMMUNOTHERAPY OF PROSTATE CANCER AND METHODS FOR THEIR USE (57) Abstract Compounds and methods for treating prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive
(71) Applicant: CORIXA CORPORATION (US/US); Suite 200, 1124 Columbia Street, Seattle, WA 98104 (US). (72) Inventors: XU, Jiangchun; 15805 Southeast 43rd Place, Bellevue, WA 98006 (US). DILLON, Davin, C.; 21607 N.E. 24th Street, Redmond, WA 98053 (US). (74) Agents: MAKI, David, J. et al.; Seed and Berry LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US). (54) Title: COMPOUNDS FOR IMMUNOTHERAPY OF PROSTATE CANCER AND METHODS FOR THEIR USE (57) Abstract Compounds and methods for treating prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive
(72) Inventors: XU, Jiangchun; 15805 Southeast 43rd Place, Bellevue, WA 98006 (US). DILLON, Davin, C.; 21607 N.E. 24th Street, Redmond, WA 98053 (US). (74) Agents: MAKI, David, J. et al.; Seed and Berry LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US). (54) Title: COMPOUNDS FOR IMMUNOTHERAPY OF PROSTATE CANCER AND METHODS FOR THEIR USE (57) Abstract Compounds and methods for treating prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive
Bellevue, WA 98006 (US). DILLON, Davin, C.; 21607 N.E. 24th Street, Redmond, WA 98053 (US). (74) Agents: MAKI, David, J. et al.; Seed and Berry LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US). (54) Title: COMPOUNDS FOR IMMUNOTHERAPY OF PROSTATE CANCER AND METHODS FOR THEIR USE (57) Abstract Compounds and methods for treating prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive
6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US). (54) Title: COMPOUNDS FOR IMMUNOTHERAPY OF PROSTATE CANCER AND METHODS FOR THEIR USE (57) Abstract Compounds and methods for treating prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive
(57) Abstract Compounds and methods for treating prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive
(57) Abstract Compounds and methods for treating prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive
(57) Abstract Compounds and methods for treating prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive
Compounds and methods for treating prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive
Compounds and methods for treating prostate cancer are provided. The inventive compounds include polypeptides containing at least a portion of a prostate tumor protein. Vaccines and pharmaceutical compositions for immunotherapy of prostate cancer comprising such polypeptides, or DNA molecules encoding such polypeptides, are also provided, together with DNA molecules for preparing the inventive

ACCCAAAAAT CCAATGCTGA ATATTTGGCT TCATTATTCC CANATTCTTT GATTGTCAAA GGATTTAATG TTGTCTCAGC TTGGGCACTT CAGTTAGGAC CTAAGGATGC CAGCCGGCAG GTTTATATAT GCAGCAACAA TATTCAAGCG CGACAACAGG TTATTGAACT TGCCCGCCAG TTNAATTTCA TTCCCATTGA CTTGGGATCC TTATCATCAG CCAGAGAGAT TGAAAATTTA CCCCTACNAC TCTTTACTCT CTGGANAGGG CCAGTGGTGG TAGCTATAAG CTTGGCCACA TTTTTTTTC CTTTATTCCT TTGTCAGA (2) INFORMATION FOR SEQ ID NO:213: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 250 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	60 120 180 240 300 328
(ii) MOLECULE TYPE: cDNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:213:	
ACTTATGAGC AGAGCGACAT ATCCNAGTGT AGACTGAATA AAACTGAATT CTCTCCAGTT TAAAGCATTG CTCACTGAAG GGATAGAAGT GACTGCCAGG AGGGAAAGTA AGCCAAGGCT CATTATGCCA AAGGANATAT ACATTTCAAT TCTCCAAACT TCTTCCTCAT TCCAAGAGTT TCTAATATTT GCATGAACCT GCTGATAANC CATGTTAANA AACAAATATC TCTCTNACCT TCTCATCGGT	60 120 180 240 250
(2) INFORMATION FOR SEQ ID NO:214:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 444 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:214:	
ACCCAGAATC CAATGCTGAA TATTTGGCTT CATTATTCCC AGATTCTTTG ATTGTCAAAG GATTTAATGT TGTCTCAGCT TGGGCACTTC AGTTAGGACC TAAGGATGCC AGCCGGCAGG TTTAATATATG CAGCAACAAT ATTCAAGCGC GACAACAGT TATTGAACTT GCCCGCCAGT TGAATTTCAT TCCCATTGAC TTGGGATCCT TATCATCAGC CANAGAGATT GAAAATTTAC CCCTACGACT CTTTACTCTC TGGAGAGGC CAGTGGTGGT AGCTATAAGC TTGGCCACAT TTTTTTTTTCC TTTATTCCTT TGTCAGAGAT GCGATTCATC CATATGCTAN AAACCAACAG AGTGACTTTT ACAAAATTCC TATAGAAATT GTGAATAAAA CCTTACCTAT AGTTGCCATT ACTTTGCTCT CCCTAATATA CCTC	60 120 180 240 300 360 420
(2) INFORMATION FOR SEQ ID NO:215:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 366 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:215:	
ACTTATGAGC AGAGCGACAT ATCCAAGTGT ANACTGAATA AAACTGAATT CTCTCCAGTT TAAAGCATTG CTCACTGAAG GGATAGAAGT GACTGCCAGG AGGGAAAGTA AGCCAAGGCT	60 120

PCT/US98/03492 WO-98/37093

122

TTCAATATTT	AAGGANATAT GCATGAACCT	GCTGATAAGC	CATGTTGAGA	AACAAATATC	TCTCTGACCT	180
	AAGCAGAGGC TTTCTACACT					300 360 366

- (2) INFORMATION FOR SEQ ID NO:216:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 260 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:216:

CTGTATAAAC AGAACTCCA	C TGCANGAGGG	AGGGCCGGGC	CAGGAGAATC	TCCGCTTGTC	60
CAAGACAGGG GCCTAAGGA	G GGTCTCCACA	CTGCTNNTAA	GGGCTNTTNC	ATTTTTTTAT	120
TAATAAAAAG TNNAAAAGG	CTCTTCTCAA	CTTTTTTCCC	TTNGGCTGGA	AAATTTAAAA	180
ATCAAAAATT TCCTNAAGT	T NTCAAGCTAT	CATATATACT	NTATCCTGAA	AAAGCAACAT	240
AATTCTTCCT TCCCTCCTT	r				260

- (2) INFORMATION FOR SEQ ID NO:217:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 262 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:217:

A COTA COTOC	CTA ACTOTAN	AAATCTTATA	ATTTCAGGAA	NAGGAACGCA	TATAATTGTA	60
						120
					GGGAATGTAG	
GGCATTCTAC	AGTTTGAGCA	AAATGCAATT	AAATGTGGAA	GGACAGCACT	GAAAAATTTT	180
ATGAATAATC	TGTATGATTA	TATGTCTCTA	GAGTAGATTT	ATAATTAGCC	ACTTACCCTA	240
ATATCCTTCA	TGCTTGTAAA	GT				262

- (2) INFORMATION FOR SEQ ID NO:218:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 205 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:218:

ACCAAGGTGG TGCATTACCG	GAANTGGATC	AANGACACCA	TCGTGGCCAA	CCCCTGAGCA	60
CCCCTATCAA CTCCCTTTTG	TAGTAAACTT	GGAACCTTGG	AAATGACCAG	GCCAAGACTC	120
AGGCCTCCCC AGTTCTACTG					180
ANAAATCAGC AGACACAGGT					205

(2) INFORMATION FOR SEQ ID NO:219:

```
Hit [ENTER] to continue ...:
                                                                 Reference No. 1
'!NA_SEQUENCE 1.0
ID
     AA447322
                standard; RNA; EST; 618 BP.
XX
AC
     AA447322;
XX
sv
     AA447322,1
XX
     07-APR-1998 (Rel. 55, Created).
07-APR-1998 (Rel. 55, Last updated, Version 1)
DT
DT
XX
     SA.CO8R PN001-Normal Human Prostate Homo sapiens cDNA clone SA.CO8
DE
DE
     5'.
XX
     EST.
KW
XX
os
     Homo sapiens (human)
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Eutheria;
OC
OC
     Primates; Catarrhini; Hominidae; Homo.
XX.
RN
     [1]
     1-618
RP
     MEDLINE; 98126432.
RX
     Nelson P.S., Ng W.-L., Schummer M., True L.D., Liu A.L., Bumgarner R.,
RA
RA
     Ferguson C., Dimak A., Hood L.;
     "An expressed-sequence-tag database of the human prostate: sequence
RT
RT
     analysis of 1168 cDNA clones";
     Genomics 47(1):12-25(1998).
RL
XX
     Contact: Nelson PS
CC
CC
     Department of Molecular Biotechnology
     University of Washington
CC
     Box 357730, HSB K360, 1705 NE Pacific, Seattle, WA 98195, USA
CC
CC
     Tel: 206 685 7336
CC
     Fax: 206 685 7301
     Email: psnels@u.washington.edu
CC
CC
     Seq primer: M13 Reverse.
XX
                      Location/Qualifiers
FH
     Key
FH
FT
                      1. .618
     source
FT
                      /db_xref="taxon:9606"
FT
                      /db_xref="ESTLIB:876"
                      /note="Organ: prostate; Vector: pSport1; Site_1: Not1;
FT
                      Site_2: Sal1; PolyA+ RNA was isolated from the prostate of
FT
                      a healthy 25 year old male organ donor. 1st strand cDNA
FT
                      was primed with oligo(dT)Not1. Double-stranded cDNA was
FT
                      ligated to Sall adapters and directionally cloned into
FT
                      pSport1 (Life Technologies). Average insert size is 1.1kb."
FT
FT
                      /sex="male"
FT
                      /organism="Homo sapiens"
                      /clone="SA.C08"
FT
                      /clone_lib="PN001-Normal Human Prostate"
FT
XX
     Sequence 618 BP; 165 A; 141 C; 118 G; 192 T; 2 other;
SQ
Aa447322 Length: 618 November 9, 1999 11:49 Type: N Check: 7801 ...
```

This Page Blank (uspto)

•						
	1	CGACCCACGC	GTCCGCCACG	CGTCCGGCTT	AATTTCAGAG	ATTCTTTCÇA
	51	TATGTTACTA	AAAAATGTTT	TGTTCAGCCT	AACATACTGA	GTTTTTTTTA
	101	ACTITCTAAA	TTATTGAATT	TCCATCATGC	ATTCATCCAA	AATTAAGGCA
	151	GACTGTTTGG	ATTCTTCCAG	TGGCCAGATG	AGCTAAATTA	AATCACAAAA
	201	GCAGATGCTT	TTGTATGATC	TCCAAATTGC	CAACTTTAAG	GAAATATTCT
	251	CTTGAAATTG	TCTTTAAAGA	TCTTTTGCAG	CTTTGCAGAT	ACCCAGACTG
•	301	AGCTGGAACT	GGAATTTGTC	TTCCTATTGA	CTCTACTTCT	TTAAAAGCGG
	351	CTGCCCATTA	CATTCCTCAG	CTGTCCTTGC	AGTTAGGTGT	ACATGTGACT
g en	401	GAGTGTTGGC	CAGTGAGATG	AAGTCTCCTC	AAAGGAAGGC	AGCATGTGTC
	451	CTTTTTCATC	CCNGCATCTT	GCTGCTGGGA	TTGTGGATAT	AACAGGAGCC
· .	501	CTGGCAGCTG	TCTCCAGAGG	ATCAAAGCCA	CACCCAAAGA	GTAAGGCAĢA
	551	TTAGAGACCA	GANAGACCTT	GACTACTTCC	CTACTTCCAC	TGCTTTTTCC
	601	TGCATTAAGC	CATGTAAA			

This Page Blank (uspto)

```
Hit [ENTER] to continue ...:
!: NA_SEQUENCE 1.0
     AA447322
                 standard; RNA; EST; 618 BP.
ID
XX
AC
     AA447322;
XX
sv
     AA447322,1
XX
     07-APR-1998 (Rel. 55, Created).
07-APR-1998 (Rel. 55, Last updated, Version 1)
DT
DT
XX
     SA.CO8R PN001-Normal Human Prostate Homo sapiens cDNA clone SA.CO8
DE
DE
XX
KW
     EST.
XX
     Homo sapiens (human)
OS
     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Eutheria;
OC
OC
     Primates; Catarrhini; Hominidae; Homo.
XX
RN
     [1]
     1-618
RP
RX
     MEDLINE; 98126432.
     Nelson P.S., Ng W.-L., Schummer M., True L.D., Liu A.L., Bumgarner R., Ferguson C., Dimak A., Hood L.;
RA
RA
     "An expressed-sequence-tag database of the human prostate: sequence
RT
     analysis of 1168 cDNA clones";
RT
     Genomics 47(1):12-25(1998).
RL
XX
CC
     Contact: Nelson PS
CC
     Department of Molecular Biotechnology
     University of Washington Box 357730, HSB K360, 1705 NE Pacific, Seattle, WA 98195, USA
CC
CC
CC
     Tel: 206 685 7336
     Fax: 206 685 7301
CC
CC
     Email: psnels@u.washington.edu
CC
     Seq primer: M13 Reverse.
XX
                       Location/Qualifiers
FH
     Key
FH
                       1. .618
/db_xref="taxon:9606"
FT
     source
FT
                       /db_xref="ESTLIB:876"
FT
                       /note="Organ: prostate; Vector: pSport1; Site_1: Not1;
FT
                       Site_2: Sall; PolyA+ RNA was isolated from the prostate of
FT
                       a healthy 25 year old male organ donor. 1st strand cDNA
FT
                       was primed with oligo(dT)Not1. Double-stranded cDNA was
FT
                       ligated to Sall adapters and directionally cloned into
FT
                       pSport1 (Life Technologies). Average insert size is 1.1kb."
FT
FT
                       /sex="male"
                       /organism="Homo sapiens"
FT
                       /clone="SA.C08"
FΤ
                       /clone_lib="PN001-Normal Human Prostate"
FT
XX
     Sequence 618 BP; 165 A; 141 C; 118 G; 192 T; 2 other;
SO
Aa447322 Length: 618 November 9, 1999 11:49 Type: N Check: 7801 ..
```

This Page Blank (uspto)

1	CGACCCACGC	GTCCGCCACG	CGTCCGGCTT	AATITCAGAG	ATTCTTTCCA
51	TATGTTACTA	AAAAATGTTT	TGTTCAGCCT	AACATACTGA	GTTTTTTTTA
101	ACTTTCTAAA	TTATTGAATT	TCCATCATGC	ATTCATCCAA	AATTAAGGCA
151	GACTGTTTGG	ATTCTTCCAG	TGGCCAGATG	AGCTAAATTA	AATCACAAAA
201	GCAGATGCTT	TTGTATGATC	TCCAAATTGC	CAACTTTAAG	GAAATATTCT
251	CTTGAAATTG	TCTTTAAAGA	TCTTTTGCAG	CTTTGCAGAT	ACCCAGACTG
301	AGCTGGAACT	GGAATTTGTC	TTCCTATTGA	CTCTACTTCT	TTAAAAGCGG
351	CTGCCCATTA	CATTCCTCAG	CTGTCCTTGC	AGTTAGGTGT	ACATGTGACT
401	GAGTGTTGGC	CAGTGAGATG	AAGTCTCCTC	AAAGGAAGGC	AGCATGTGTC
451	CTTTTTCATC	CCNGCATCTT	GCTGCTGGGA	TTGTGGATAT	AACAGGAGCC
501	CTGGCAGCTG	TCTCCAGAGG	ATCAAAGCCA	CACCCAAAGA	GTAAGGCAĢA
551	TTAGAGACCA	GANAGACCTT	GACTACTTCC	CTACTTCCAC	TGCTTTTTCC
601	TGCATTAAGC	CATGTAAA			

•

his Page Blank (uspto)